The aim of our study was to assess the effects of vitamin D supplementation on lipid profile in patients with arterial hypertension (AH). Material and methods. A randomized, prospective, cohort, single-center study of 115 individuals with stage II AH (50.9±7.3 years) was performed. The duration of the follow-up was 15,8±1,8 months. 43 individuals did not receive cholecalciferol, 72 received cholecalciferol at the daily dose of 2000 IU from 3 to 12 months. By means of regression analysis we determined that intake of cholecalciferol and stably high level of serum 25( ОН )D were positively correlated (p<0,05) with increased level of HDL, Apo A1, as well as with the dynamics of these values and negatively correlated (p<0,05) with the levels of TC, AI, Apo B, Apo B/Apo A1. Thus, intake of cholecalciferol and stably high level of serum 25( ОН )D have a positive effect on lipid profile in patients with AH.

The article gives a review of new literature data of epidemiologic, clinical, experimental studies and results of metaanalyses, demonstrating the relationship between vitamin D and increased risk of arterial hypertension, atherosclerosis, diabetes mellitus, metabolic syndrome as well as their more severe course and development of complications secondary to vitamin D deficiency. The results of certain studies aimed at evaluation of the effectiveness of vitamin D supplementation for prevention and treatment of cardiovascular diseases are presented. The given review is intended for raising doctors’ awareness of possible negative consequences of vitamin D deficiency and suggests a closer monitoring of vitamin D status and its correction.

The aim of the study was to assess ambulatory blood pressure monitoring (ABPM) values and their dynamics while correcting vitamin D deficiency/insufficiency in women with arterial hypertension (AH) stage II in early postmenopausal period. Results: In vitamin D serum deficiency/insufficiency (18.2±9.5 ng/ml) we observed higher (р

The aim of the study was to assess plasma renin activity (PRA) and its relationship with endothelial function in women with arterial hypertension (AH) stage II in premenopausal (group I) and early postmenopausal (group II) periods after correction of vitamin D deficiency/insufficiency. Results: in the subgroups with deficit (IB, IIB) and without deficit of vitamin D (IA, IIA) in plasma at baseline there were no significant differences in terms of: PRA (IB0.83 [0.61, 1.03] vs IA-0, 83 [0.54, 1.03] ng / ml / hr; IIB 0.88 [0.72, 2.31] vs IIA of 0.81 [0.53, 1.25] ng / ml / hr; EZVD(IB 7.2 [-21.8, 29.6 vs] IA 0.7 [-14.4, 28.9]%, IIB 3.9 [-3.3, 25.7] vs IIA 4.3 [-13.4, 23.9]%); nitrate / nitrite (IB 17,7 ± 8,5 vs 18,8 ± 8,0 IA mol / L; IIB-16,8 ± 8,5 vs IIA14,7 ± 5,8 mmol / l); PWV (IB 4.2 [3.9, 6.9] vs IA 5.6 [4.2, 7.3] m / s; IIB5.7 [4.5, 7.0] vs IIA5.2 [4.1, 6.3] m / s. When correcting vitamin D status in plasma PRA, PWV decreased significantly, while endothelium function improved.

At present a number of pathogenetic mechanisms of arterial hypertension (AH) in perimenopausal women are being discussed. The purpose of the given article is to study the increasing role of rennin-angiotensin-aldosterone system (RAAS) and vitamin D deficiency/insufficienty in pathogenesis of AH in this category of patients.